Quality of life in patients with newly diagnosed ovarian cancer accompanied by peritoneal carcinomatosis

Close metadata

OBJECTIVE

To assess the quality of life in patients with newly diagnosed ovarian cancer accompanied by peritoneal carcinomatosis after standard combined treatment and pressurized intraperitoneal aerosol chemotherapy (PIPAC).

MATERIAL AND METHODS

The study included 164 women with newly diagnosed ovarian cancer who underwent hysterectomy with adnexectomy and omentectomy. After intraoperative randomization, 79 patients were included in the study group (1st group) who received three PIPAC sessions in addition to standard combined treatment. Women in the 2nd group (n=85) received standard combined treatment. The total follow-up period for patients was 90 days. The general condition and quality of life were assessed on days 14, 50, and 90 using the ECOG scale and the EORTC QLQ-C30 questionnaire (version 3), respectively.

RESULTS

The results showed that the general condition and quality of life after primary surgical treatment did not differ significantly. At 3 months of follow-up, the scores characterizing the general condition of women on the ECOG scale in the PIPAC group were 1.75 times higher compared to the 2nd group (p=0.017). Similarly, in this group, the scores characterizing the quality of life on the EORTC-QLQ-C30 questionnaire (version 3) were 3.5 points higher compared to the control group (p=0.025). In the control group, there were 72 cases of recurrence and 11 deaths, while in the study group, there were 41 cases of recurrence and 4 deaths. Mathematical analysis of the data revealed that the median recurrence-free survival in the study group was 8 months longer than in the control group.

CONCLUSION

The quality of life and general condition of patients in the PIPAC group were better than those in the control group. This phenomenon remained stable throughout the study.

Keywords:

ovarian cancer

peritoneal carcinomatosis

pressurized intraperitoneal aerosol chemotherapy

locally advanced cancer

quality of life

Authors:

Dzasokhov A.S.

Moscow Regional Oncological Dispensary

ORCID: 0000-0003-4977-3533

Kostin A.A.

Peoples’ Friendship University of Russia (RUDN University)

ORCID: 0000-0002-0792-6012

Astashov V.L.

Moscow Regional Oncological Dispensary

ORCID: 0000-0003-1075-3797

Turiev A.V.

Moscow Regional Oncological Dispensary

ORCID: 0000-0001-9284-4873

Korovyakova E.A.

Peoples’ Friendship University of Russia (RUDN University)

ORCID: 0000-0002-3149-8089

Received:

23.06.2023

Accepted:

27.09.2023

List of references:

Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, Magalhaes I. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Semin Cancer Biol. 2022;86(Pt. 3):207-223. https://doi.org/10.1016/j.semcancer.2022.03.027
Kaprin AD, Starinskii VV, Shakhzadova AO, eds. Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Ministerstva zdravookhraneniya Rossiiskoi Federatsii; 2022. (In Russ.).
Cabasag CJ, Fagan PJ, Ferlay J, Vignat J, Laversanne M, Liu L, van der Aa MA, Bray F, Soerjomataram I. Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer. 2022;151(9):1535-1541. https://doi.org/10.1002/ijc.34002
Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for newly diagnosed epithelial ovarian cancer — a review. J Ovarian Res. 2022;15(1):88. https://doi.org/10.1186/s13048-022-01020-1
Ritch SJ, Telleria CM. The transcoelomic ecosystem and epithelial ovarian cancer dissemination. Front Endocrinol (Lausanne). 2022;13:886533. https://doi.org/10.3389/fendo.2022.886533
Brown Y, Hua S, Tanwar PS. Extracellular matrix in high-grade serous ovarian cancer: advances in understanding of carcinogenesis and cancer biology. Matrix Biol. 2023;118:16-46. https://doi.org/10.1016/j.matbio.2023.02.004
Dzasokhov AS, Kostin AA, Astashov VV, Andreev MA, Turiev AV, Uskov AD. Dynamic assessment of intraperitoneal aerosol chemotherapy under pressure impact on peritoneal carcinomatosis in ovarian cancer (immediate results). South Russian Journal of Cancer. 2023;4(1):43-51. https://doi.org/10.37748/2686-9039-2023-4-1-5
Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol. 2016;13(4):255-261. https://doi.org/10.1038/nrclinonc.2015.224
Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20(4):952. https://doi.org/10.3390/ijms20040952
Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019;37(16):1380-1390. https://doi.org/10.1200/JCO.18.01568
Vergote I, Harter P, Chiva L. Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer. Cancer. 2019;125(suppl 24):4594-4597. https://doi.org/10.1002/cncr.32496
Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open. 2022;7(5):100586. https://doi.org/10.1016/j.esmoop.2022.100586
Mehta SS, Gelli M, Agarwal D, Goéré D. Complications of cytoreductive surgery and HIPEC in the treatment of peritoneal metastases. Indian J Surg Oncol. 2016;7(2):225-229. https://doi.org/10.1007/s13193-016-0504-6
Roensholdt S, Detlefsen S, Mortensen MB, Graversen M. Response evaluation in patients with peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). J Clin Med. 2023;12(4):1289. https://doi.org/10.3390/jcm12041289
Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013;20(7):2311-2316. https://doi.org/10.1245/s10434-012-2840-2
Neeman E, Gresham G, Ovasapians N, Hendifar A, Tuli R, Figlin R, Shinde A. Comparing physician and nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ratings as predictors of clinical outcomes in patients with cancer. Oncologist. 2019;24(12):e1460-e1466. https://doi.org/10.1634/theoncologist.2018-0882
Mansur A, Gritskevich AA, Kostin AA, Kul’chenko NG, Pospelova OM, Kalinycheva GE. Quality of life of patients with paraurethral cysts. Andrology and Genital Surgery. 2022;23(4):74-80. (In Russ.). https://doi.org/10.17650/2070-9781-2022-23-4-74-80
Alyami M, Hübner M, Grass F, Bakrin N, Villeneuve L, Laplace N, Passot G, Glehen O, Kepenekian V. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368-e377. https://doi.org/10.1016/S1470-2045(19)30318-3
Tempfer CB, Hartmann F, Hilal Z, Rezniczek GA. Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report. BMC Cancer. 2017;17(1):26. https://doi.org/10.1186/s12885-016-3004-8
De Simone M, Vaira M, Argenziano M, Berchialla P, Pisacane A, Cinquegrana A, Cavalli R, Borsano A, Robella M. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin, cisplatin, and doxorubicin in patients with peritoneal carcinomatosis: an open-label, single-arm, Phase II clinical trial. Biomedicines. 2020;8(5):102. https://doi.org/10.3390/biomedicines8050102
Odendahl K, Solass W, Demtröder C, Giger-Pabst U, Zieren J, Tempfer C, Reymond MA. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Eur J Surg Oncol. 2015;41(10):1379-1385. https://doi.org/10.1016/j.ejso.2015.06.001

Close metadata